The 71st Annual Meeting of the American Academy of Neurology (AAN) was held in Philadelphia, Pennsylvania, from May 4-10, 2019.
As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2020.
This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.
This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.
This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.
The challenges faced by biosimilar developers are not unlike those confronting their branded counterparts. First, companies must develop high-quality biosimilars and obtain regulatory approval. Next, they must then navigate the vast array of commercial nuances that exist at the national level in order for their products to be used in the clinical setting.
Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advances in the pipeline that aim to invigorate the field in its second generation.
Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.
Highlights: The budget impact of multiple myeloma is set to increase While multiple myeloma represents a relatively small patient population in comparison to other cancers, payers are concerned about the rising spend on the indication. New biologic therapies are increasingly gaining label expansions in earlier treatment lines, and with life expectancies improving, patients are requiring […]
This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.
A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.
A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.
This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.
This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.
This interview covers hepatocellular carcinoma treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also disused are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!